文献速递浆细胞疾病

达雷妥尤单抗联合硼替佐米、来那度胺和地塞米松治疗不适合移植的新诊断多发性骨髓瘤:CEPHEUS研究亚组分析

Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS.
PubMed 文献 · J Clin Oncol · 2026-09-25

The phase III CEPHEUS trial (ClinicalTrials.gov identifier: NCT03652064) of patients with transplant-ineligible (TIE) or transplant-deferred newly diagnosed multiple myeloma (NDMM; N = 395) demonstrated improved overall minimal residual disease (MRD) negativity rates among patien…

要点

  • DVRd组持续MRD阴性≥12个月和≥24个月率均显著更高
  • DVRd降低疾病进展或死亡风险49%(HR=0.51,95%CI 0.35-0.74)

核心结论

  • DVRd在TIE NDMM患者中较VRd显著改善MRD阴性率和PFS,支持其作为标准治疗。

研究设计与样本

  • CEPHEUS III期试验的TIE亚组分析,共纳入289例患者(DVRd组144例,VRd组145例)。

主要发现

  • 总生存数据尚不成熟,但显示DVRd有获益趋势(HR=0.66,95%CI 0.42-1.03)。

关键数值与推荐

  • MRD阴性定义为10⁻⁵灵敏度。
  • TIE患者定义为18-70岁且伴有≥1种可能影响大剂量化疗联合自体干细胞移植耐受性的合并症,或年龄≥70岁。

临床怎么用

  • 对于不适合移植的新诊断多发性骨髓瘤患者,DVRd方案可带来更深缓解和更长PFS,应考虑作为治疗选择。

局限性

  • 总生存数据尚不成熟。
  • 本文为亚组分析,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase III CEPHEUS trial (ClinicalTrials.gov identifier: NCT03652064) of patients with transplant-ineligible (TIE) or transplant-deferred newly diagnosed multiple myeloma (NDMM; N = 395) demonstrated improved overall minimal residual disease (MRD) negativity rates among patients achieving ≥complete response and progression-free survival (PFS) with daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd. We present efficacy and safety outcomes in the CEPHEUS TIE subgroup (N = 289; DVRd, n = 144; VRd, n = 145). Patients were either age 18-70 years with ≥1 comorbidity likely to negatively affect tolerability of high-dose chemotherapy with autologous stem cell transplantation or age ≥70 years. At a median follow-up of 58.7 months, the MRD negativity rate (10-5) was 60.4% (DVRd) versus 39.3% (VRd; P = .0004). Rates of sustained MRD negativity (10-5) for ≥12 months (47.2% v 28.3%; P = .0010) and ≥24 months (40.3% v 22.8%; P = .0015) were significantly higher with DVRd. Risk of disease progression or death was 49% lower for DVRd versus VRd (hazard ratio [HR], 0.51 [95% CI, 0.35 to 0.74]; P = .0003). Although immature, overall survival favored DVRd (HR, 0.66 [95% CI, 0.42 to 1.03]). Adverse events were consistent with known safety profiles. This analysis demonstrates that the deep responses achieved with DVRd translate into improved PFS in patients with TIE NDMM, reinforcing DVRd as a standard of care.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Usmani SZ, Facon T, Hungria V, et al. Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUS. J Clin Oncol. 2026. PMID: 42789828. doi:10.1200/JCO-26-00401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。